Have a feature idea you'd love to see implemented?
Let us know!
ETON Eton Pharmaceuticals Inc
Price (delayed)
$10.75
Market cap
$277.74M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.22
Enterprise value
$261.73M
Eton Pharmaceuticals, Inc. is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The company currently owns or receives royalties from three FDA-approved products, including ALKINDI®
Highlights
The debt has declined by 26% year-on-year and by 11% since the previous quarter
The company's net income rose by 18% QoQ
The quick ratio has contracted by 47% YoY but it has grown by 6% from the previous quarter
ETON's equity is up by 19% since the previous quarter but it is down by 5% year-on-year
The gross margin has contracted by 17% YoY
Key stats
What are the main financial stats of ETON
Market
Valuations
Earnings
Shares outstanding
25.84M
Market cap
$277.74M
Enterprise value
$261.73M
Price to earnings (P/E)
N/A
Price to book (P/B)
17.38
Price to sales (P/S)
7.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.28
Revenue
$35.95M
EBIT
-$6.02M
EBITDA
-$4.9M
Free cash flow
$2.11M
Per share
Balance sheet
Liquidity
EPS
-$0.22
Free cash flow per share
$0.08
Book value per share
$0.62
Revenue per share
$1.39
TBVPS
$1.16
Total assets
$35.84M
Total liabilities
$19.86M
Debt
$4.25M
Equity
$15.98M
Working capital
$10.02M
Debt to equity
0.27
Current ratio
1.51
Quick ratio
1.31
Net debt/EBITDA
3.27
Margins
Efficiency
Dividend
EBITDA margin
-13.6%
Gross margin
60.7%
Net margin
-15.2%
Operating margin
-11%
Return on assets
-16.8%
Return on equity
-36.3%
Return on invested capital
N/A
Return on capital employed
-37.4%
Return on sales
-16.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ETON stock price
How has the Eton Pharmaceuticals stock price performed over time
Intraday
3.07%
1 week
2.77%
1 month
27.37%
1 year
202.82%
YTD
145.43%
QTD
79.17%
Financial performance
How have Eton Pharmaceuticals's revenue and profit performed over time
Revenue
$35.95M
Gross profit
$21.84M
Operating income
-$3.95M
Net income
-$5.48M
Gross margin
60.7%
Net margin
-15.2%
The company's operating margin rose by 33% QoQ
The net margin has grown by 27% since the previous quarter
The operating income has grown by 25% from the previous quarter
The company's net income rose by 18% QoQ
Growth
What is Eton Pharmaceuticals's growth rate over time
Valuation
What is Eton Pharmaceuticals stock price valuation
P/E
N/A
P/B
17.38
P/S
7.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.28
ETON's EPS is up by 15% since the previous quarter
The stock's price to book (P/B) is 135% more than its last 4 quarters average of 7.4 and 29% more than its 5-year quarterly average of 13.5
ETON's equity is up by 19% since the previous quarter but it is down by 5% year-on-year
ETON's P/S is 135% above its last 4 quarters average of 3.3 but 97% below its 5-year quarterly average of 266.0
The revenue is up by 11% QoQ and by 7% YoY
Efficiency
How efficient is Eton Pharmaceuticals business performance
ETON's return on sales is up by 24% since the previous quarter
The return on assets has grown by 21% since the previous quarter
Eton Pharmaceuticals's ROE has increased by 17% from the previous quarter
Dividends
What is ETON's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ETON.
Financial health
How did Eton Pharmaceuticals financials performed over time
ETON's total assets is 80% more than its total liabilities
The quick ratio has contracted by 47% YoY but it has grown by 6% from the previous quarter
Eton Pharmaceuticals's current ratio has decreased by 42% YoY but it has increased by 8% from the previous quarter
The debt is 73% smaller than the equity
The debt has declined by 26% year-on-year and by 11% since the previous quarter
ETON's debt to equity is down by 25% since the previous quarter and by 21% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.